Pendopharm has obtained the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat, an on-demand investigational treatment for hereditary angioedema (HAE), in Canada under a licensing agreement with Kalvista Pharmaceuticals, the developer of the therapy. “We look forward to collaborating with Pendopharm, whose deep…
News
In the years following treatment with the gene-editing therapy lonvoguran ziclumeran, or lonvo-z — also known as NTLA-2002 — most people with hereditary angioedema (HAE) taking part in a clinical trial have been completely free from swelling attacks without the need for long-term preventive therapy. That’s according to…
Navenibart, an experimental treatment from Astria Therapeutics to prevent swelling episodes in people with hereditary angioedema (HAE), continues to show strong and sustained benefits in a long-term clinical trial. New data from the ALPHA-SOLAR Phase 2 (NCT06007677) open-label extension study show treatment with navenibart every three…
Oral deucrictibant continued to control swelling attacks as a preventative therapy and rapidly stop swelling attacks as an on-demand treatment for hereditary angioedema (HAE), according to new data from the open-label extension portions of two clinical trials. All open-label extension participants said that preventive deucrictibant controlled their HAE…
The U.S. Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii) to prevent swelling attacks caused by hereditary angioedema (HAE) in adults and adolescents, ages 12 and older, adding the U.S. to the countries where the medication is available. Developed by CSL Behring, it’s the only treatment…
The oral medication Orladeyo (berotralstat) is now approved in Colombia as a preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval, from Colombia’s National Institute of Drug and Food Surveillance (INVIMA), follows the therapy’s approval in…
Orladeyo (berotralstat) is now approved for reimbursement in the Netherlands following a recommendation from healthcare government agency Zorginstituut Nederland. The treatment is used for routine prevention, or prophylaxis, of swelling attacks in people 12 years and older with hereditary angioedema (HAE). With this decision,…
Kalvista Pharmaceuticals’ sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), rapidly stopped the progression of swelling attacks, according to interim data from a two-year open-label extension study. It was also effective against attacks involving the larynx (voice box) and abdomen, as well as those rated as severe or…
Recognizing a problem early and treatment can help avoid life-threatening complications when swelling of the larynx, or voice box, caused by hereditary angioedema (HAE) blocks the airways. That’s according to a report that describes the case of a man in China with hereditary angioedema-induced laryngeal edema (HALE), which can…
The use of Orladeyo (berotralstat) — widely approved as a preventive treatment for hereditary angioedema (HAE) — can help reduce the rates of swelling attacks in people with HAE of different ages, according to new data from clinical trials and real-world analyses. Biocryst Pharmaceuticals, the developer of the…
Recent Posts
- A roller coaster of a year gave me new insights about living with HAE
- 1-year trial data: Orladeyo cuts swelling attacks in young children
- 1 lonvo-z dose keeps most HAE patients attack-free up to 3 years
- For many of us, becoming a patient advocate wasn’t optional
- FDA extends Orladeyo approval to children as young as 2